DEVELOPMENTAL FUNDS The scientific leadership has transformed The Jackson Laboratory Cancer Center (JAXCC) in the current grant cycle, resulting in an expanded cancer focus. New expertise in human genetics and genomics is tightly integrated with mouse genomics expertise, supporting work to model the complexity of the human cancer genome. Integral to this transformation was recruitment of new members through faculty hiring and engagement of existing faculty with complementary transdisciplinary expertise. The JAXCC has expanded its capabilities in cancer genomics and cancer systems biology, built strength in immuno-oncology and the tumor microenvironment, and established robust translational partnerships to move basic research quickly towards clinical impact. The membership has expanded profoundly, driven by a strengthened, cancer-focused leadership on both the Bar Harbor and Farmington campuses, which saw the addition of 22 new members since 2013 (18 in the current grant cycle). Developmental funds have been crucial factors in fueling the JAXCC's growth and productivity. In the current grant cycle, New Investigator funds were used to support nine junior faculty members, engaging them with the Senior Leaders who mentored them as they developed their research plans. Awards are made throughout the year with new investigators submitting a formal program plan for a two-year award. While still early for most, the progress and productivity of these junior faculty point to the efficacy of this approach. These awards have supported work leading to 12 publications and 14 external grants totaling $5,064,892. In the next cycle, funds are requested for support of new investigator awards, which will be leveraged by significant institutional commitment of funds. Plans call for adding 4 to 5 new junior-level JAXCC members in the next five years, with a continuing emphasis on cancer genomics and immuno-oncology. Research will rely on the ongoing development and validation of a variety of in vivo, ex vivo, and in silico systems to model cancer complexity. The Pilot Project program is an essential part of the plan to achieve the JAXCC's strategic goals. The Senior Leadership sets priorities and solicits pilot proposals annually through a request for applications (RFA) that targets specific goals. Projects are awarded based on the quality of the science, their anticipated contribution to one or more strategic goals, and the plan for securing federal funding for the mature project. In the previous grant cycle, 17 awards have supported work leading to 14 publications and 14 grants totaling $7,619,270 (direct costs). Funds are requested to support 2-3 new pilot projects in the first 2 years, open to all JAXCC members and leveraging institutional match. As the membership matures, we will fund 3-5 pilot funds in years 3 to 5. Taken together, the Developmental Funds will support the JAXCC in fostering a collaborative and dynamic cancer program capable of advancing precision cancer medicine.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA034196-34
Application #
9854062
Study Section
Subcommittee H - Clinical Groups (NCI)
Project Start
Project End
Budget Start
2019-12-01
Budget End
2020-11-30
Support Year
34
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Jackson Laboratory
Department
Type
DUNS #
042140483
City
Bar Harbor
State
ME
Country
United States
Zip Code
04609
Richter, Wolfgang F; Christianson, Gregory J; Frances, Nicolas et al. (2018) Hematopoietic cells as site of first-pass catabolism after subcutaneous dosing and contributors to systemic clearance of a monoclonal antibody in mice. MAbs 10:803-813
Tamura, Ryo; Yoshihara, Kosuke; Saito, Tetsuya et al. (2018) Novel therapeutic strategy for cervical cancer harboring FGFR3-TACC3 fusions. Oncogenesis 7:4
Rutherford, Sarah C; Fachel, Angela A; Li, Sheng et al. (2018) Extracellular vesicles in DLBCL provide abundant clues to aberrant transcriptional programming and genomic alterations. Blood 132:e13-e23
Barthel, Floris P; Wesseling, Pieter; Verhaak, Roel G W (2018) Reconstructing the molecular life history of gliomas. Acta Neuropathol 135:649-670
Kim, Hyunsoo; Kumar, Pooja; Menghi, Francesca et al. (2018) High-resolution deconstruction of evolution induced by chemotherapy treatments in breast cancer xenografts. Sci Rep 8:17937
Winer, Benjamin Y; Shirvani-Dastgerdi, Elham; Bram, Yaron et al. (2018) Preclinical assessment of antiviral combination therapy in a genetically humanized mouse model for hepatitis delta virus infection. Sci Transl Med 10:
Barthel, Floris P; Johnson, Kevin C; Wesseling, Pieter et al. (2018) Evolving Insights into the Molecular Neuropathology of Diffuse Gliomas in Adults. Neurol Clin 36:421-437
Schechter, Lisa M; Creely, David P; Garner, Cherilyn D et al. (2018) Extensive Gene Amplification as a Mechanism for Piperacillin-Tazobactam Resistance in Escherichia coli. MBio 9:
Tarchini, Basile; Longo-Guess, Chantal; Tian, Cong et al. (2018) A spontaneous mouse deletion in Mctp1 uncovers a long-range cis-regulatory region crucial for NR2F1 function during inner ear development. Dev Biol 443:153-164
Vian, Laura; P?kowska, Aleksandra; Rao, Suhas S P et al. (2018) The Energetics and Physiological Impact of Cohesin Extrusion. Cell 173:1165-1178.e20

Showing the most recent 10 out of 1156 publications